<DOC>
	<DOCNO>NCT00068029</DOCNO>
	<brief_summary>The purpose study compare safety tolerability combination therapy Sandostatin LAR plus Pegvisomant Sandostatin LAR alone Pegvisomant alone .</brief_summary>
	<brief_title>Pegvisomant And Sandostatin LAR Combination Study</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Diagnosis acromegaly Received previous radiation and/or surgical treatment GH ( Growth Hormone ) produce pituitary adenoma require medical therapy due failure normalize GH ( Growth Hormone ) and/or IGFI result primary treatment Patients receive Sandostatin LAR minimum 6 month prior enrollment Presence condition may result abnormal GH ( Growth Hormone ) and/or IGFI concentration Patients current medical therapy Sandostatin LAR AST/ALT &gt; = 3xULN ( upper limit normal ) Pituitary adenoma within 3mm optic chiasm confirm recent MRI Visual field defect ( except postsurgical stable residual defect ) Unable self administer drug Radiotherapy within 12 month enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>